Puma Biotechnology (PBYI)
(Real Time Quote from BATS)
$3.72 USD
+0.06 (1.64%)
Updated Jul 22, 2024 03:03 PM ET
4-Sell of 5 4
A Value A Growth C Momentum A VGM
Balance Sheet
Fiscal Year End for Puma Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 96 | 81 | 91 | 102 | 121 |
Receivables | 48 | 40 | 33 | 26 | 29 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 7 | 5 | 7 | 3 | 3 |
Other Current Assets | 5 | 8 | 9 | 15 | 14 |
Total Current Assets | 156 | 134 | 140 | 146 | 166 |
Net Property & Equipment | 1 | 1 | 2 | 2 | 3 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 61 | 71 | 66 | 74 | 40 |
Deposits & Other Assets | 5 | 5 | 5 | 5 | 6 |
Total Assets | 231 | 222 | 227 | 244 | 235 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 7 | 6 | 11 | 12 | 19 |
Current Portion Long-Term Debt | 34 | 0 | 0 | 14 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 53 | 66 | 93 | 82 | 69 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 1 | 2 | 2 | 0 |
Total Current Liabilities | 99 | 77 | 110 | 114 | 91 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 66 | 98 | 97 | 84 | 95 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 5 | 13 | 6 | 32 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 177 | 200 | 229 | 250 | 217 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,399 | 1,388 | 1,364 | 1,332 | 1,295 |
Retained Earnings | -1,345 | -1,367 | -1,367 | -1,338 | -1,278 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 53 | 22 | -2 | -6 | 17 |
Total Liabilities & Shareholder's Equity | 231 | 222 | 227 | 244 | 235 |
Total Common Equity | 53 | 22 | -2 | -6 | 17 |
Shares Outstanding | 47.50 | 45.60 | 40.80 | 39.70 | 38.90 |
Book Value Per Share | 1.13 | 0.47 | -0.06 | -0.15 | 0.45 |
Fiscal Year End for Puma Biotechnology, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 107 | 96 | 85 | 74 |
Receivables | NA | 25 | 48 | 29 | 31 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 7 | 7 | 6 | 8 |
Other Current Assets | NA | 4 | 5 | 6 | 5 |
Total Current Assets | NA | 143 | 156 | 125 | 119 |
Net Property & Equipment | NA | 1 | 1 | 1 | 1 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 58 | 61 | 63 | 66 |
Deposits & Other Assets | NA | 5 | 5 | 6 | 5 |
Total Assets | NA | 214 | 231 | 204 | 200 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 9 | 7 | 5 | 8 |
Current Portion Long-Term Debt | NA | 45 | 34 | 23 | 11 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 38 | 53 | 34 | 36 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 1 | 1 | 1 | 1 |
Total Current Liabilities | NA | 98 | 99 | 67 | 60 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 55 | 66 | 77 | 88 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 5 | 13 | 13 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 163 | 177 | 165 | 170 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 1,401 | 1,399 | 1,396 | 1,394 |
Retained Earnings | NA | -1,350 | -1,345 | -1,357 | -1,363 |
Other Equity | NA | 0 | 0 | 0 | 0 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 51 | 53 | 39 | 30 |
Total Liabilities & Shareholder's Equity | NA | 214 | 231 | 204 | 200 |
Total Common Equity | 0 | 51 | 53 | 39 | 30 |
Shares Outstanding | 48.20 | 48.20 | 47.50 | 47.50 | 46.70 |
Book Value Per Share | 0.00 | 1.06 | 1.13 | 0.82 | 0.65 |